
The acquisition brings Gallant’s experimental stem cell treatments for chronic gingivostomatitis and osteoarthritis in dogs and cats into Dechra’s portfolio.
synctest_0303_Changepublishenddate
Pub end date set to 01/02/4000 when article was initially published to web.

